Drug Approval | November 17, 2025
EMA recommends authorization of Teizeild to delay Type 1 diabetes onset
This is the first drug to receive a recommendation for this preventative indication in the European Union
This is the first drug to receive a recommendation for this preventative indication in the European Union
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Diversifying its portfolio to include late-phase antiviral agent
The investment in land is Rs. 19.85 crore
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Subscribe To Our Newsletter & Stay Updated
